%PDF-1.3
%
6 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
10 0 obj
<>stream
application/pdf
CAN-2021-0114-ver9-Kaufmann_2P 1..7
2021-12-16T09:34:25+05:30
Arbortext Advanced Print Publisher 9.0.114/W
2021-12-31T16:28:34-08:00
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
uuid:fd335a27-4afb-4e0e-b338-1323143e4fdc
uuid:d8cdac7a-1fdc-4304-83cd-6d5ed0b98d6f
endstream
endobj
11 0 obj
<>stream
x+ |
endstream
endobj
12 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
19 0 obj
<>stream
x+ |
endstream
endobj
20 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
21 0 obj
<>stream
x+ |
endstream
endobj
22 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
23 0 obj
<>stream
x+ |
endstream
endobj
24 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
26 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
10.4607 0 0 10.4607 62.022 698.2297 Tm
0 0 0 rg
0 Tc
0 Tw
(Introduction)Tj
/F6 1 Tf
10.959 0 0 10.959 62.022 685.2471 Tm
[(Cannabidiol)-488.5(\(CBD\))-486.1(self-medication)-487.9(is)-493.4(becoming)-483.9(in-)]TJ
0 -1.1795 TD
[(creasingly)-350.5(common)-350.7(in)-347.4(the)-354.7(United)-346.3(States)-354.5(with)-345.8(surveys)]TJ
0 -1.1847 TD
[(showing)-564.4(that)-564.5(the)-566.8(percent)-568.7(of)-564.4(individuals)-566(who)-568.2(have)]TJ
0 -1.1795 TD
[(tried)-321.1(CBD)-323.7(has)-323.4(increased)-321.8(from)-319.6(14%)-325.1(in)-321.6(2019)-318.8(to)-320.6(at)-326.7(least)]TJ
0 -1.1847 TD
[(33.3%)-207.5(in)-207.8(2020.)]TJ
8.2191 0 0 7.3052 125.0645 638.3054 Tm
(1,2)Tj
10.959 0 0 10.959 137.0267 633.4297 Tm
[(Although)-204.4(a)-204.5(very-high-dose)-208.4(CBD)-204.8(is)-203.7(as-)]TJ
-6.8441 -1.1795 TD
[(sociated)-287.3(with)-288.9(elevations)-282.5(in)-290.5(liver)-285.1(tests)-290.3(\(LTs\))-288.1(in)-285.4(children)]TJ
T*
[(being)-473.7(treated)-471.1(for)-469.4(epilepsy)-474.2(and)-473(in)-471.6(normal)-468.9(adults,)-472.2(all)]TJ
0 -1.1847 TD
[(other)-297.7(studies)-301(of)-295.4(CBD)-297.9(use)-298.5(have)-299.7(found)-297.4(no)-298.9(such)-295.2(associa-)]TJ
0 -1.1795 TD
(tion.)Tj
8.2191 0 0 7.3052 81.9779 586.5447 Tm
(3,4)Tj
10.959 0 0 10.959 95.4708 581.6691 Tm
[(With)-344.5(the)-344.3(sole)-347.9(exception)-346.1(of)-347.1(diarrhea,)-348.4(all)-346(of)-347.1(the)]TJ
-3.0522 -1.1847 TD
[(adverse)-434.2(outcomes)-432.7(in)-435.4(childhood)-431.3(epilepsy)-432.8(studies)-435.5(\(ab-)]TJ
0 -1.1795 TD
[(normal)-298.2(liver)-300.6(function)-302(tests,)-299.9(somnolence,)-297.5(sedation,)-301.2(and)]TJ
0 -1.1847 TD
[(pneumonia\))-572.9(were)-568.8(limited)-568.5(to)-568.9(instances)-575.2(where)-565.4(CBD)]TJ
0 -1.1795 TD
[(may)-388.2(have)-392.8(interacted)-392.2(with)-387.2(other)-390.8(medications,)-391.1(such)-393.5(as)]TJ
0 -1.1847 TD
[(clobazam)-298.2(and/or)-301(sodium)-298.6(valproate.)]TJ
8.2191 0 0 7.3052 217.9275 521.7448 Tm
(3)Tj
10.959 0 0 10.959 72.9637 503.9432 Tm
[(In)-233.1(a)-230.3(phase)-230.7(1)-229.7(trial)-233.8(of)-228.1(70)-231.8(normal)-231(adults)-229.8(who)-226.8(consumed)]TJ
-.9984 -1.1847 TD
[(1500)-163.6(mg/day)-629.8(of)-621.3(CBD)-628.9(along)-623.1(with)-625.2(various)-625.1(epileptic)]TJ
0 -1.1795 TD
[(drugs,)-572(not)-571.1(a)-571.8(single)-566.6(individual)-573(developed)-572.7(abnormal)]TJ
T*
[(LT,)-354.5(however,)-351.7(in)-352.6(a)-354.5(similar)-356.9(phase)-349.7(1)-353.9(trial)-352.8(of)-357.5(adults)-348.8(con-)]TJ
0 -1.1847 TD
[(suming)-319.7(only)-320.3(CBD)-323.7(at)-321.5(the)-318.5(same)-319.6(dose/day,)-326.7(7)-317.7(o)0(f)-321.2(1)0(6)-325(indi-)]TJ
0 -1.1795 TD
[(viduals)-460.5(\(44%\))-461.6(had)-457.1(elevated)-463.2(LT)-458.7(with)-459.7(5)-457.3(having)-460.3(levels)]TJ
0 -1.1847 TD
[(meeting)-338.7(criteria)-336.7(for)-340.1(drug-induced)-338.5(liver)-336.8(injury.)]TJ
8.2191 0 0 7.3052 266.2865 431.0928 Tm
(4,5)Tj
10.959 0 0 10.959 279.6661 426.2172 Tm
(Why)Tj
-19.8598 -1.1795 TD
[(such)-393.5(vast)-389.3(differences)-392(in)-394(ndings)-390.7(exist)-393.8(is)-389.9(unknown)-391.7(at)]TJ
0 -1.1847 TD
[(this)-550.2(time,)-547.6(however,)-548.2(these)-547.3(very)-549.2(high)-547.9(daily)-547.8(doses)-551.9(of)]TJ
0 -1.1795 TD
[(CBD)-318.6(are)-324.6(much)-318(greater)-321.1(than)-320.4(the)-323.7(daily)-320.2(dosage)-321(typically)]TJ
0 -1.1847 TD
[(consumed)-266.9(by)-262.9(CBD)-266.8(self-medicating)-266.1(users)-268.9(in)-264.7(the)-266.8(United)]TJ
0 -1.1795 TD
(States.)Tj
.9984 -1.1795 TD
[(Laboratories)-260.3(set)-257.9(the)-256.4(97.5%)-259.2(value)-257.3(of)-259.2(LT)-256.9(in)-259.5(adult)-262.7(indi-)]TJ
-.9984 -1.1847 TD
[(viduals)-382.9(with)-382.1(no)-386.8(disease)-383.8(as)-383.7(the)-380.6(upper)-386.3(limit)-381.9(of)-383.3(normal)]TJ
0 -1.1795 TD
[(\(ULN\).)-304.4(However,)-298.5(the)-303(prevalence)-302.9(of)-305.7(elevated)-302.8(LT)-303.5(in)-300.9(the)]TJ
0 -1.1847 TD
[(general)-625.4(adult)-619.7(populations)-619.6(is)-622.7(estimated)-625.1(at)-621.6(between)]TJ
0 -1.1795 TD
[(10%)-423.4(and)-426.4(20%)-423.4(and)-426.4(has)-426.9(been)-423.9(rising)-427.6(over)-424.4(the)-421.9(years.)]TJ
8.2191 0 0 7.3052 291.4582 301.6062 Tm
(6,7)Tj
10.959 0 0 10.959 62.022 283.748 Tm
[(The)-456.6(prevalence)-458.1(of)-460.9(elevated)-458(alanine)-454.7(aminotransferase)]TJ
T*
-.0001 Tc
[(\(ALT\))-342.9(and)-338.6(elevated)-344.3(aspartate)-342.4(aminotransferase)-344.6(\(AST\))]TJ
0 -1.1847 TD
0 Tc
[(in)-466.4(the)-468.5(United)-465.3(States)-468.3(in)-466.4(years)-464.8(19992002)-463.9(were)-470.5(8.9%)]TJ
0 -1.1795 TD
-.0002 Tc
[(and)-437(4.9%,)-442.8(respectively.)]TJ
8.2191 0 0 7.3052 164.8062 249.7889 Tm
0 Tc
(7)Tj
10.959 0 0 10.959 173.537 244.9133 Tm
[(Using)-436.4(any)-441.9(LT)-438(by)-433.6(itself)-439.8(as)-440.6(a)]TJ
-10.1756 -1.1847 TD
[(screening)-481.6(instrument)-482.2(for)-479.7(liver)-481.7(disease)-482.1(or)-481(damage)-484.4(is)]TJ
0 -1.1795 TD
[(not)-540.1(as)-538.9(useful)-536(as)-538.9(using)-541.9(multiple)-534.4(LTs,)-538.9(that)-538.7(is,)-539.2(ALT,)]TJ
T*
[(AST,)-403(alkaline)-396.4(phosphatase)-401.3(\(ALP\),)-399.2(and)-400.6(total)-402.4(bilirubin)]TJ
0 -1.1847 TD
(\(TB\).)Tj
8.2191 0 0 7.3052 85.0393 197.9716 Tm
(3)Tj
10.959 0 0 10.959 94.1669 193.096 Tm
[(This)-471(study)-474.3(was)-467.1(undertaken)-477.2(to)-470.6(determine)-469.2(the)]TJ
-2.9332 -1.1795 TD
[(prevalence)-406.4(of)-404(elevated)-401.1(levels)-406.7(of)-404(these)-402.4(four)-404.6(LTs)-405.1(in)-404.4(an)]TJ
0 -1.1847 TD
[(adult)-299(population)-300.7(of)-300.5(self-medicating)-297.1(CBD)-297.9(users.)]TJ
/F3 1 Tf
10.4607 0 0 10.4607 62.022 140.9385 Tm
[(Materials)-302.5(and)-298.4(Methods)]TJ
/F6 1 Tf
10.959 0 0 10.959 62.022 128.0126 Tm
[(Adults,)-429.2(1875)-424.4(years)-428.6(of)-429.9(age)-427.2(across)-426.1(the)-427.1(United)-429.1(States,)]TJ
T*
[(known)-330.1(to)-325.8(be)-330.7(taking)-327.2(CBD)-323.7(orally)-327.6(for)-329.7(a)-328.6(minimum)-328.5(of)-326.4(30)]TJ
0 -1.1795 TD
[(days,)-455.1(were)-454.9(recruited)-457.1(from)-454.1(consumers)-452(of)-455.7(12)-454.3(individ-)]TJ
0 -1.1847 TD
[(ual)-562.2(CBD)-561.7(product)-567.2(companies)-560.6(to)-563.7(participate)-561.6(in)-564.7(this)]TJ
0 -1.1795 TD
[(decentralized,)-550.3(observational,)-547.1(IRB-approved)-547.5(study)-551.9(in)]TJ
0 -1.1847 TD
[(accordance)-208.4(with)-206.2(the)-209.8(ethical)-207.4(standards)-206.8(on)-210.9(human)-206(exper-)]TJ
22.9068 57.9137 TD
[(imentation.)-387.7(An)-391.2(app-based,)-390.6(21CFR)-387(Part)-383.6(11)-392.2(decentral-)]TJ
0 -1.1847 TD
[(ized)-550.4(clinical)-542.9(study)-541.6(platform)-543.6(\(ValidCare)-544.9(Study\))-544.7(was)]TJ
0 -1.1795 TD
-.0001 Tc
[(used)-301.1(to)-294.8(securely)-293.2(automate)-293.7(consent)-298.2(inclusion/exclusion)]TJ
0 -1.1847 TD
0 Tc
(criteria.)Tj
1.0036 -1.1795 TD
[(Exclusion)-350.7(criteria)-357.4(included)-354.2(individuals)-353.9(with)-351(known)]TJ
-1.0036 -1.1847 TD
[(liver)-502.3(disease,)-502.1(liver)-497.2(function)-498.6(impairment,)-500.2(allergies)-499.4(to)]TJ
0 -1.1795 TD
[(CBD,)-426.5(or)-424.1(taking)-425.5(the)-427.1(following:)-421.2(valproate,)-422.8(Vitamin)-426.1(A,)]TJ
T*
[(clobazam,)-219.8(cyclosporin,)-211(phenytoin,)-218.9(uvoxamine,)-214(isonia-)]TJ
0 -1.1847 TD
[(zid,)-262.1(ritonavir,)-263.9(clarithromyci)5.3(n,)-265.3(diltiazem,)-257.9(erythromycin,)]TJ
0 -1.1795 TD
[(grapefruit)-599.8(juice,)-599.7(itraconazole,)-597.3(ketoconazole,)-600(nefazo-)]TJ
0 -1.1847 TD
[(done,)-298.5(ritonavir,)-300.1(telithromycin,)-298.5(or)-294.8(verapamil.)-297.7(Individu-)]TJ
0 -1.1795 TD
[(als)-511.3(selected)-516.1(were)-511.9(sent)-508.4(their)-511.9(standard)-513.9(CBD)-504.8(regimen)]TJ
0 -1.1847 TD
[(\(full-spectrum,)-324.8(broad)-317.3(spectrum,)-320.4(or)-320.7(CBD-isolate\))-320.7(from)]TJ
0 -1.1795 TD
[(the)-411.6(company)-413.2(of)-409.2(their)-413.6(choice.)-409(Demographic)-407.9(informa-)]TJ
0 -1.1847 TD
[(tion,)-377.6(medical)-375.8(history,)-375.9(reasons)-376.6(for)-376.3(taking,)-378.3(dosage,)-372(and)]TJ
0 -1.1795 TD
[(current)-429.3(medications)-428(were)-423.9(collected)-425(through)-425.6(the)-427.1(app,)]TJ
T*
[(along)-250.6(with)-247.6(daily)-252.9(journaling)-245.2(information)-251.4(on)-247.1(dosage,)-253(ad-)]TJ
0 -1.1847 TD
[(verse)-304.8(effects,)-296.8(and)-302.3(efcacy.)]TJ
1.0036 -1.1795 TD
[(At)-423.3(the)-422(end)-426.7(of)-424.7(30)-423.2(days)-419.6(of)-424.7(journaling,)-425.6(blood)-420.1(draws)]TJ
-1.0036 -1.1847 TD
[(were)-341.1(performed)-339.1(locally)-341.2(and)-338.5(serum)-338.2(was)-343(sent)-337.7(to)-341.3(one)-338.1(of)]TJ
0 -1.1795 TD
[(two)-326.5(national)-327.4(laboratories,)-323.3(where)-327.5(LTs)-322.3(were)-325.6(performed.)]TJ
0 -1.1847 TD
[(The)-472.1(different)-473.8(laboratories)-468.9(had)-472.6(different)-473.8(ULN)-468.6(values)]TJ
0 -1.1795 TD
[(for)-567.7(their)-568.8(populations.)-567.2(To)-567.3(normalize)-566.8(the)-566.8(ALT)-568.4(data)]TJ
0 -1.1847 TD
[(from)-407.5(the)-401.3(different)-406.5(laboratories,)-400.9(ALT)-408(values)-400.3(were)-408.4(ad-)]TJ
0 -1.1795 TD
[(justed)-235.3(to)-232.6(the)-235.7(percentile)-232.4(of)-233.3(the)-235.7(ULN)-230.7(for)-231.4(their)-232.5(laboratory.)]TJ
0 -1.1847 TD
[(All)-473.6(individuals)-472.8(with)-470(elevated)-468.3(ALT)-470.1(values)-472.7(were)-470.5(con-)]TJ
0 -1.1795 TD
[(tacted)-473(and)-467.8(offered)-471.5(a)-468.3(follow-up)-468(LT.)-473.5(Medical)-468.3(history,)]TJ
T*
[(medication)-357.5(history,)-355.3(and)-354(cannabinoid)-354.7(use)-355.4(history)-356(data)]TJ
0 -1.1847 TD
[(were)-320.4(collected)-311.1(for)-319.4(the)-313.3(time)-315.5(period)-317(between)-317(the)-313.3(testing)]TJ
0 -1.1795 TD
[(points.)-342(Individuals)-342.9(were)-336(encouraged)-342.1(to)-336.1(provide)-340.1(infor-)]TJ
0 -1.1847 TD
[(mation)-319.2(on)-319.6(LT)-319(ordered)-319.5(by)-319.8(personal)-317.2(medical)-324(providers,)]TJ
0 -1.1795 TD
[(regardless)-320.1(of)-310.9(whether)-317(they)-315.7(consented)-314(to)-315.4(the)-313.3(follow-up)]TJ
0 -1.1847 TD
(testing.)Tj
1.0036 -1.1795 TD
-.0207 Tc
[(Quanti)-3.8(tative)-396.2(dat)-3.2(a)-395.9(wer)-3.3(e)-391(anal)-3.5(yzed)-395.7(us)-3.3(ing)-395.6(t)1.9(he)-396.2(Wil)-3.5(c)2.1(oxon)]TJ
-1.0036 -1.1847 TD
-.0212 Tc
[(r)-3.8(a)-3.2(nk-s)-3.8(um)-450.8(or)-453.9(s)-3.8(i).8(gned-r)-3.8(ank)-458.2(t)1.4(est)-3.7(s)-453.9(and)-458.2(q)-2.6(uali)-4.3(tati)-4.3(ve)-458.8(data)-458.5(by)]TJ
0 -1.1795 TD
-.0201 Tc
[(the)-416.3(c)2.7(hi-square)-416.3(t)2.5(est)-416.5(f)1.9(or)-416.6(ho)4(mogeneity)-415.7(o)-1.2(r)-416.6(a)-416(b)4(i)-3.2(nomial)-416.7(test)]TJ
T*
-.0191 Tc
[(using)-399.2(a)4(n)-398.9(e)-1.4(xact)]TJ
/F7 1 Tf
6.1199 0 TD
0 Tc
(p)Tj
/F6 1 Tf
.4604 0 TD
-.0195 Tc
[(-value)-400.2(calcu)3.9(l)-2.3(a)3.6(t)-2(ion.)-396.4(Non)4.2(l)-2.3(a)3.6(boratory)-394.4(v)-1.2(ari-)]TJ
-6.5803 -1.1847 TD
[(ables)-374.5(a)-1.4(n)4.3(a)-1.4(lyzed)-378.8(i)2.6(nclu)4(de)-379.4(w)5.8(e)-1.7(ight,)-375.6(h)-.5(eigh)4.6(t,)-375.6(bo)4.7(dy)-378.8(mass)-374.5(index)]TJ
0 -1.1795 TD
-.0189 Tc
[(\(BMI)3.7(\),)-240.6(s)3.7(e)-1.2(x,)-240.6(a)4.2(g)-.6(e)3.9(,)-240.6(fo)5.2(rm)-241.5(o)5.2(f)-240(CBD,)-240.6(c)3.9(o)0(mpo)5.2(s)-1.5(ition)-238.4(o)0(f)-240(C).8(BD)6.6(,)-240.6(a)-.9(l)3.5(c)-1.2(o-)]TJ
0 -1.1847 TD
-.018 Tc
[(hol)4.4(ic)-202.1(d)5.4(r)-.6(i)4(n).5(ks)-197.2(per)-202.4(d)5.4(ay)5.5(,)-203.5(n).5(umb)6.1(e)-.3(r)-202.4(o)6.1(f)-202.9(m)2.5(ed)5.4(ic)4.8(al)-202.5(c)4.8(o).9(nd)5.4(it)4.6(io)6.1(ns,)-198.3(n).5(um-)]TJ
0 -1.1795 TD
-.0206 Tc
[(ber)-592.9(o)3.5(f)-593.5(p)-2.4(rescri)-3.7(bed)-592.1(d)-2.4(rugs)-3.2(,)-594.1(n)3.1(umber)-592.9(o)-1.7(f)-593.5(o)3.5(t)-3.1(h)3.4(er)-592.9(ther)-3.2(api)-3.7(e)2.2(s)-3.2(,)]TJ
0 -1.1847 TD
-.0215 Tc
[(number)-355.9(of)-356.5(over)-4.1(-t)-4(he-)-3.8(c)1.3(ount)-4(er)-355.9(tr)-4.1(eatme)-3.8(n)-3(ts)-4.1(,)-351.9(a)-3.5(nd)-355.1(number)-355.9(of)]TJ
0 -1.1795 TD
-.0203 Tc
[(ot)-2.8(her)-297.8(C)-.6(BD)-300.1(tr)-2.9(eatments)-302.9(being)-302.1(u)3.1(s)-2.9(e)2.5(d.)]TJ
1.0036 -1.1847 TD
0 Tc
[(Different)-337.2(laboratories)-334.4(had)-338.1(different)-339.3(ULN)-339.3(values)-338.2(for)]TJ
-1.0036 -1.1795 TD
[(their)-454.9(populations.)-448.2(To)-453.5(normalize)-453(the)-447.8(ALT)-454.6(data)-450.9(from)]TJ
0 -1.1847 TD
[(the)-463.3(different)-468.6(laboratories)7(,)-464.9(ALT)-464.9(values)-462.4(were)-460.1(adjusted)]TJ
0 -1.1795 TD
[(to)-227.5(the)-230.5(percentile)-227.2(of)-228.1(the)-225.4(ULN)-230.7(for)-226.2(their)-227.3(laboratory.)-227.6(A)-223.5(for-)]TJ
T*
[(ward)-438.6(stepwise)-431.6(linear)-432.4(regression)-433(was)-436.1(used)-435.5(to)-434.4(identify)]TJ
0 -1.1847 TD
[(predictors)-381.6(of)-378.1(LT)-375.9(values.)-378.9(The)-373.8(algorithm)-379.8(was)-374(validated)]TJ
0 -1.1795 TD
[(by)-299.1(repeated)-302.7(application)-300.9(to)-299.9(subsamples.)]TJ
/F3 1 Tf
9.9626 0 0 9.9626 62.022 754.3557 Tm
(2)Tj
40.7955 0 TD
[(KAUFMA)-9.5(NN)-304.7(ET)-299.4(AL.)]TJ
ET
endstream
endobj
35 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
10.4607 0 0 10.4607 59.7543 516.6991 Tm
0 0 0 rg
0 Tc
0 Tw
(Results)Tj
/F6 1 Tf
10.959 0 0 10.959 59.7543 503.7164 Tm
[(A)-394.2(total)-386.9(of)-388.5(28,121)-387.5(individuals)-390.1(from)-392(across)-389.9(the)-390.9(United)]TJ
0 -1.1795 TD
[(States)-442.5(were)-439.4(invited)-440.1(to)-444.7(participate)-437.4(in)-440.6(this)-441.6(study.)-442.6(One)]TJ
0 -1.1847 TD
[(thousand)-594.3(four)-590.9(hundred)-592.1(seventy-ve)-588.6(were)-589.4(enrolled,)]TJ
0 -1.1795 TD
[(and)-395.4(839)-394.3(fully)-393.4(completed)-395.3(the)-390.9(study)-396.7(with)-392.4(blood)-389(draws)]TJ
0 -1.1847 TD
[(for)-634.9(LTs.)-637.2(The)-632.4(839)-632.3(individuals)-638.4(who)-630.3(completed)-633.2(the)]TJ
0 -1.1795 TD
[(study)-386.4(came)-381.5(from)-386.8(43)-381.9(states,)-380.2(including)-388.1(Alaska)-383(and)-379.9(the)]TJ
0 -1.1847 TD
[(District)-396.6(of)-388.5(Columbia.)-394.3(Of)-392.6(these,)-391.3(548)-389.1(\(65.3%\))-395.8(were)-392.9(fe-)]TJ
0 -1.1795 TD
[(male)-454.3(and)-452.3(291)-446(\(34.7%\))-452.7(were)-449.8(male.)-453.6(Age)-451.4(ranged)-450.7(from)]TJ
0 -1.1847 TD
[(18)-573.3(to)-568.9(75)-568.1(with)-568.3(the)-566.8(mean)]TJ
/F4 1 Tf
10.9568 0 TD
()Tj
/F6 1 Tf
.7139 0 TD
[(SD)-572.2(of)-569.5(45.5)]TJ
/F4 1 Tf
4.9507 0 TD
(+)Tj
/F6 1 Tf
.7191 0 TD
[(13.1)-564.3(years.)]TJ
-17.3405 -1.1795 TD
[(There)-364.6(was)-358.5(no)-360.9(statistical)-361.8(difference)-362.8(in)-363(age)-359.9(between)-363.6(fe-)]TJ
T*
[(males)-411.1(and)-410.9(males)-411.1(\(45.8)]TJ
/F4 1 Tf
9.4566 0 TD
()Tj
/F6 1 Tf
.7139 0 TD
[(13.2)-414.3(and)-410.9(44.8)]TJ
/F4 1 Tf
5.794 0 TD
()Tj
/F6 1 Tf
.7191 0 TD
[(12.7,)-413.6(respec-)]TJ
-16.6835 -1.1847 TD
[(tively\).)-455.8(The)-451.4(percent)-449.7(of)-450.6(individuals)-452.1(versus)-457.6(the)-447.8(length)]TJ
0 -1.1795 TD
[(of)-300.5(their)-299.8(CBD)-297.9(use)-303.7(is)-296.8(shown)-299.5(in)-300.9(Figure)-296.9(1.)]TJ
1.0036 -1.1847 TD
[(Table)-204.1(1)-203.9(shows)-202.3(the)-199.5(number)-204.4(and)-204(percent)-206.5(of)-202.3(individuals)]TJ
-1.0036 -1.1795 TD
[(taking)-254.8(the)-251.2(various)-247.5(compositions)-253.3(of)-248.8(CBD)-251.3(and)-250.5(compares)]TJ
0 -1.1847 TD
[(the)-416.8(average)-412.8(daily)-413.3(doses.)-416.7(Full-spectrum)-413.6(hemp)-416.2(oil)-412.6(was)]TJ
0 -1.1795 TD
[(taken)-494.7(by)-495.7(55.7%,)-491.3(CBD-isolate)-487.8(by)-495.7(40.5%,)-491.3(and)-493.7(broad-)]TJ
0 -1.1847 TD
[(spectrum)-352.2(CBD)-344.4(by)-350.8(3.8%.)-349.5(Overall,)-349.6(the)-349.5(mean)]TJ
/F4 1 Tf
17.6302 0 TD
()Tj
/F6 1 Tf
.7191 0 TD
[(SD)-349.8(daily)]TJ
-18.3492 -1.1795 TD
[(dose)-724.5(of)-724.7(CBD)-727.2(\(mg\))-723.7(was)-725.8(50.3)]TJ
/F4 1 Tf
13.4399 0 TD
(+)Tj
/F6 1 Tf
.7139 0 TD
[(40.7)-166(mg/day.)-727.3(Full-)]TJ
-14.1538 -1.1795 TD
[(spectrum)-414.2(users)-418.2(daily)-413.3(dose)-414.1(was)-415.4(40.0)]TJ
/F4 1 Tf
15.0591 0 TD
(+)Tj
/F6 1 Tf
.7191 0 TD
[(36.8)-166(mg,)-410.6(CBD-)]TJ
-15.7782 -1.1847 TD
[(isolate)-657.7(users)-656.9(\(63.9)]TJ
/F4 1 Tf
8.0339 0 TD
(+)Tj
/F6 1 Tf
.7191 0 TD
[(42.8)-166(mg,\),)-656.6(and)-654.1(broad-spectrum)]TJ
-8.753 -1.1795 TD
[(users)-460.3(\(56.5)]TJ
/F4 1 Tf
4.6559 0 TD
(+)Tj
/F6 1 Tf
.7139 0 TD
[(26.5)-166(mg\).)-460.7(The)-456.6(upper)-463.9(limit)-459.5(of)-455.7(the)-458.2(range)]TJ
-5.3698 -1.1847 TD
[(for)-303.8(each)-295.2(group)-302.2(is)-302(several)-295.5(times)-303.3(that)-295.5(of)-300.5(the)-297.8(mean.)]TJ
1.0036 -1.1795 TD
[(The)-394.5(forms)-395.3(by)-397.4(which)-394.1(the)-396.1(different)-401.3(compositions)-392.9(of)]TJ
-1.0036 -1.1847 TD
[(CBD)-478.9(were)-480.8(taken)-484.4(are)-479.8(listed)-479.8(in)-482(Table)-478.2(2.)-482.5(Almost)-478.6(half)]TJ
22.912 46.0826 TD
[(\(49.7%\))-447.5(of)-455.7(the)-447.8(participants)-455.4(used)-451(a)-452.8(tincture,)-453(whereas)]TJ
0 -1.1847 TD
[(22.1%)-217.8(used)-223.4(a)-220(capsule)-222.3(or)-222.4(pill,)-224.7(13.9)-217.7(used)-223.4(an)-222.2(edible)-219.4(formu-)]TJ
0 -1.1795 TD
-.0001 Tc
[(lation,)-358.1(12.6%)-352.4(used)-363.2(a)-354.6(nanotechnology-treated)-362.6(product,)]TJ
0 -1.1847 TD
0 Tc
[(and)-498.9(1.7%)-500.2(used)-502.8(an)-501.5(additive)-505.2(that)-497.3(could)-504.8(be)-501.5(added)-499.5(to)]TJ
0 -1.1795 TD
[(a)-297.6(slushy)-301.4(or)-300(food.)]TJ
.9984 -1.1847 TD
[(Th)22.4(e)-241(a)12.8(ve)20.4(r)12.2(a)12.8(ge)-233.1(d)13(a)12.8(il)18.5(y)-240.4(d)13(o)13.7(s)0(e)-228.8(o)0(f)-228.1(t)0(h)20.8(e)-241(n)13.3(a)0(n)21(o)0(t)20.8(e)12.5(c)12.5(h)0(n)21.8(o)0(l)20.6(o)13.7(gy)21(-)12.6(t)12.3(re)19.5(a)12.8(t)12.3(ed)]TJ
-.9984 -1.1795 TD
[(C)14.5(B)0(D)-214.1(w)14.8(as)-212.9(si)18.7(g)13.1(n)13.3(i)20.2(c)12.5(a)0(n)21(t)12.3(l)12(y)-224.9(l)12(o)0(w)23.4(e)0(r)-213.3(t)12.3(ha)21.3(n)-224.6(a)12.8(ny)-211.5(of)-212.6(t)12.3(h)0(e)-211.8(o)0(t)20.8(h)13.7(er)-213.3(fo)20.2(r)12.2(m)10.2(s)]TJ
T*
[(o)13.7(f)-448.8(CB)23.3(D)-450.5(u)13(se)19.5(d)13(.)-454.5(T)13.9(h)0(i)20.2(s)-448.2(n)13.3(a)0(n)21(o)0(t)20.8(e)12.5(c)12.5(h)0(n)21.8(o)0(l)20.6(o)13.7(gy)21(-)12.6(t)12.3(re)19.5(a)12.8(t)12.3(ed)-440.1(CB)23.3(D)-450.5(w)0(a)22.4(s)]TJ
0 -1.1847 TD
[(a)-437.3(f)11.6(ul)19.9(l)12(-)12.6(s)12.2(p)0(e)20.3(c)12.5(tr)19.3(u)13(m)-439.9(p)13(r)0(o)20.8(d)13(uc)20.3(t)12.3(.)-439(W)11(h)0(e)21(n)-436.7(it)-431.3(w)14.8(a)0(s)-430.2(r)12.2(e)12.5(m)10.2(ov)21.6(e)12.5(d)-442.2(f)11.7(r)12.2(o)13.7(m)]TJ
0 -1.1795 TD
[(t)12.3(h)13.7(e)-504.8(a)0(n)21(a)12.8(ly)20(s)12.2(i)11.7(s,)-494(th)20.8(e)-504.8(a)12.8(ve)20.4(r)12.2(a)0(g)20.7(e)-504.8(d)13(a)0(i)19.3(l)12(y)-504.2(d)13(os)20.8(e)-504.8(o)13.7(f)-505.7(f)11.7(ul)19.9(l)12(-)12.6(s)12.2(p)0(e)20.3(c)12.5(tr)19.3(u)13(m)]TJ
0 -1.1847 TD
-.0145 Tc
[(CB)-14.5(D)-301(i)-2.8(nc)-14.5(rea)-14.5(s)5.3(ed)-311.9(to)-311.2(63)-14.5(.2)]TJ
/F4 1 Tf
9.0427 0 TD
0 Tc
(+)Tj
/F6 1 Tf
.7087 0 TD
[(4)13.4(1)0(.)19.3(8)-152.1(m)10.2(g)0(.)-286.2(T)0(h)22.4(e)12.5(re)-285.7(wa)22.4(s)-298.2(n)13.3(o)-296.7(s)12.2(t)12.3(a)0(t)19.9(i)11.7(s)12.2(t)0(i)18.8(-)]TJ
-9.7514 -1.1795 TD
[(c)12.5(a)12.8(l)-401.8(d)0(i)19.5(f)11.6(f)11.7(e)0(r)19.5(e)12.5(nc)20.6(e)-401.4(i)11.7(n)-400.5(a)0(v)20.7(e)12.5(ra)19.8(g)13.1(e)-406.5(d)13(o)13.7(sa)19.8(g)13.1(e)-401.4(be)21(t)12.3(w)0(e)22.1(e)0(n)-393.2(t)12.3(h)13.7(e)-401.4(di)19.5(f)11.7(f)11.7(e)0(r)19.5(e)12.5(nt)]TJ
0 -1.1847 TD
[(c)12.5(o)13.7(m)10.2(p)0(o)21.6(s)12.2(i)11.7(t)0(i)18.8(o)13.7(ns)-791.8(o)13.7(r)-800(f)11.7(o)13.7(rm)22.4(s)-800(o)0(f)-786.8(C)0(B)23.3(D)-802.3(u)13(s)12.2(ed)-791.8(w)14.8(h)0(e)21(n)-798.9(t)12.3(h)0(e)]TJ
0 -1.1795 TD
[(n)13.3(a)0(n)21(o)13.7(te)19.6(c)12.5(h)0(n)21.8(o)13.7(lo)20.6(g)13.1(y)0(-)20.5(t)12.3(r)12.2(e)0(a)20.1(t)12.3(ed)-497(CB)23.3(D)-507.4(w)0(a)22.5(s)-510.3(e)12.5(x)0(c)20.1(l)12(ud)20.9(e)12.5(d)-509.5(f)11.7(r)0(o)20.8(m)-507.2(t)12.3(h)0(e)]TJ
0 -1.1847 TD
-.013 Tc
[(an)-13(a)8(l)-1(ys)-13(i)5.7(s)-.8(.)]TJ
.9984 -1.1795 TD
0 Tc
[(Table)-235.1(3)-240.1(shows)-238.6(the)-235.7(prevalence)-240.8(of)-238.5(the)-235.7(LT)-236.2(in)-238.8(this)-239.8(study.)]TJ
-.9984 -1.1795 TD
[(The)-420.3(number)-416.5(and)-421.3(percentage)-416.5(of)-419.5(individuals)-421.1(with)-418.3(ele-)]TJ
0 -1.1847 TD
[(vated)-381.2(LT)-365.6(we)22.1(re)14.4(:)-371.7(A)0(L)17.8(T)-374.1(9)13.4(.)0(1)14.1(%)0(,)-361.5(A)0(S)16.9(T)-374.1(4)13.4(.)0(0)14.1(%)0(,)-361.5(A)0(L)17.8(P)-374.3(1)13.4(.)0(8)14.1(%)0(,)-361.5(a)0(n)15.8(d)]TJ
0 -1.1795 TD
[(TB)-427.4(1.)19.3(4%)18.5(.)-439(T)13.9(he)-429.1(pr)14.9(e)12.5(v)0(a)15.6(l)12(en)15.5(c)12.5(e)0(s)-430.5(o)0(f)-429.9(e)12.5(le)14.2(v)13.1(a)0(t)19.9(e)0(d)-429.7(A)0(L)17.8(T)-436.1(an)15.8(d)-437(A)0(S)22.1(T)]TJ
0 -1.1847 TD
[(we)22.1(re)-404.7(si)18.7(gn)16.1(i)11.7()0(c)15.8(a)0(n)21(t)0(l)14(y)-411.1(hi)20.2(gh)16.4(e)12.5(r)-412(th)15.6(a)12.8(n)-416(t)12.3(h)0(e)-403.2(2)0(.)19.3(5)0(%)-405.7(p)0(r)20.1(e)0(v)15.2(a)12.8(le)19.3(nc)15.5(e)-411.7(i)0(n)]TJ
0 -1.1795 TD
-.0161 Tc
[(a)-732.7(n)-16.1(orm)-5.9(a)-16.1(l)-725.9(p)-16.1(opu)-16.1(l)-1.4(at)-16.1(io)-16.1(n)-728.8(w)-16.1(it)-16.1(h)-724.7(n)-16.1(o)-723.6(m)-5.9(e)-16.1(d)-.9(ic)-16.1(al)-733.5(co)-16.1(nd)-16.1(it)-16.1(io)-16.1(ns)]TJ
0 -1.1847 TD
0 Tc
(\()Tj
/F7 1 Tf
.5018 0 TD
(p)Tj
/F4 1 Tf
.6311 0 TD
(<)Tj
/F6 1 Tf
.7087 0 TD
[(0.)14.1(0)13.4(0)0(0)16.5(0)0(1)-454.3(f)11.7(or)-455.2(AL)23(T)-462(a)0(n)15.8(d)-462.9(0.)19.3(00)16.5(5)-462.5(f)11.6(or)-455.2(AS)22.1(T\))15.5(.)-459.7(H)0(o)18.4(w)0(e)17(v)0(e)20.4(r)0(,)]TJ
-1.8416 -1.1795 TD
[(t)12.3(h)0(e)15.8(y)-255.9(we)17(re)-249.5(no)16.7(t)-256.7(s)0(i)18.7(g)0(n)16.1(i)11.7(c)15.8(a)12.8(n)0(t)15.3(l)12(y)-261.1(d)13(if)13(f)11.6(e)0(r)19.5(e)0(n)15.5(t)-256.7(fr)18.7(om)-250.3(th)20.8(ei)13.8(r)-256.8(r)0(e)19.5(p)0(o)16.4(r)0(t)19.3(e)0(d)]TJ
0 -1.1847 TD
[(pr)20.1(ev)15.2(a)12.8(l)0(e)14.2(n)13.3(ce)14.6(s)-334.4(i)0(n)-331.9(t)12.3(he)-330.8(ge)20.4(ne)15.5(r)12.2(a)0(l)-332.1(a)12.8(du)15.7(l)12(t)-339.5(U.)21(S.)-333.1(po)21.6(pu)15.7(l)12(a)0(t)14.8(i)11.7(on)-329.9(\()11.9(8)0(.)14.1(9)13.4(%)]TJ
0 -1.1795 TD
[(f)11.7(o)0(r)-284.5(A)0(L)23(T)-291.3(an)15.8(d)-292.2(4)13.4(.9)14.1(%)-289.8(f)11.7(or)-284.5(AS)22.1(T\))15.5(.)]TJ
8.2191 0 0 7.3052 433.5873 391.918 Tm
(6)Tj
10.959 0 0 10.959 321.7889 374.0597 Tm
[(Th)22.4(e)-194.4(p)0(r)20.1(e)0(v)20.4(a)0(l)19.7(e)12.5(nc)15.5(e)-189.3(o)0(f)-181.6(T)0(B)-184.2(\()11.9(1.)19.3(4%)23.6(\))-195(w)0(a)22.4(s)-194.7(s)12.2(i)11.7(gn)16.1(i)11.7()0(c)21(a)0(n)21(t)0(l)19.2(y)-193.8(l)12(e)12.5(ss)-182.5(th)20.8(at)]TJ
-.9984 -1.1795 TD
[(t)12.3(h)0(e)-434.2(n)13.3(or)20.8(m)10.2(a)0(l)-430.4(p)0(o)16.4(p)13(ul)19.9(at)19.9(i)11.7(o)0(n)-433.4(p)0(r)20.1(e)0(v)20.4(a)0(l)19.7(e)12.5(nc)15.5(e)-437.6(o)0(f)-435.1(2)13.4(.5)19.3(%)-439.8(\()]TJ
/F7 1 Tf
18.3079 0 TD
(p)Tj
/F4 1 Tf
.6363 0 TD
(<)Tj
/F6 1 Tf
.7087 0 TD
-.0121 Tc
[(0.0)-12.1(5)4.4(\),)]TJ
-19.6529 -1.1795 TD
0 Tc
[(a)12.8(n)0(d)-361.6(t)12.3(he)-356.6(pr)14.9(e)12.5(v)0(a)20.7(l)12(en)15.5(c)12.5(e)-370.3(o)13.7(f)-371.2(AL)23(P)-369.2(w)0(a)22.5(s)-370.6(no)21.9(t)-370.5(d)0(i)19.5(f)11.7(fe)19(re)19.5(nt)-357.2(th)20.8(an)-361.9(t)12.3(h)0(e)]TJ
0 -1.1847 TD
[(n)13.3(o)0(r)20.8(m)10.2(al)-321.8(po)16.4(p)13(u)0(l)19.9(a)0(t)19.9(i)11.7(on)-324.7(p)13(r)0(e)19.5(v)0(a)20.7(l)0(e)19.3(n)0(c)20.6(e)-334.1(of)-321.2(2.)19.3(5%)18.5(.)-330.4(T)0(h)22.4(e)-334.1(pr)20.1(ev)20.4(al)19.7(en)20.6(ce)]TJ
0 -1.1795 TD
[(o)13.7(f)-459.1(t)12.3(h)0(o)17.1(s)12.2(e)-458.3(h)13.7(av)20.7(in)19.8(g)-457.6(e)0(i)19(t)12.3(he)15.8(r)-453.4(a)0(n)-449.8(e)12.5(l)12(e)0(v)20.4(a)0(t)19.9(e)0(d)-450.4(A)0(L)23(T)-456.8(or)-444.8(AS)16.9(T)-456.9(w)14.8(as)]TJ
0 -1.1847 TD
[(1)13.4(0)0(.)19.3(2)0(%)-198.8(\()0(8)20.2(6)-209(in)19.8(di)19.5(vi)19.6(du)20.9(al)19.7(s\))19(,)-211.4(w)0(h)18.2(i)11.7(c)12.5(h)-213.9(w)14.8(a)0(s)-202.6(n)0(o)21.9(t)-210.1(st)19.3(a)12.8(t)0(i)18.8(s)0(t)19.3(i)11.7(ca)20.1(ll)18.9(y)-209.3(d)0(i)19.5(f)0(f)18.1(e)12.5(r-)]TJ
0 -1.1795 TD
[(e)12.5(n)0(t)-398.6(t)12.3(ha)16.1(n)-405.7(t)12.3(he)-398(re)19.5(po)16.4(r)12.2(t)12.3(ed)-398.7(pr)20.1(ev)15.2(a)12.8(l)12(en)15.5(c)12.5(e)-406.5(in)-399.2(th)20.8(e)-406.5(g)0(e)15.2(n)13.3(er)19.5(al)-399.4(a)12.8(d)0(u)15.7(l)12(t)]TJ
0 -1.1847 TD
[(U.)21(S)12.8(.)-294.1(p)13(o)0(p)16.4(u)13(la)19.7(t)12.3(i)0(o)20.2(n)-291.9(\()11.9(9)0(.)19.3(8)0(%)18.5(\))11.9(.)]TJ
8.2191 0 0 7.3052 411.6472 288.2834 Tm
(6)Tj
10.959 0 0 10.959 321.7889 270.4818 Tm
[(Table)-204.1(4)-209(shows)-202.4(the)-204.7(prevalence)-204.6(of)-207.4(abnormal)-204.5(LT)-205.2(for)-205.6(dif-)]TJ
-.9984 -1.1847 TD
[(ferent)-468.7(levels)-468.8(of)-466.1(elevation)-465.5(of)-471.3(ALT.)-464.2(Of)-470.2(76)-464.6(individuals)]TJ
0 -1.1795 TD
[(with)-299.3(elevated)-302.8(A)14.5(L)18.9(T)19.1(,)-237.2(6)18.6(5)-234.9(w)20(e)17.7(r)17.4(e)]TJ
/F4 1 Tf
11.2154 0 TD
(<)Tj
/F6 1 Tf
.6984 0 TD
(2)Tj
/F4 1 Tf
.626 0 TD
()Tj
/F6 1 Tf
.957 0 TD
-.0185 Tc
[(ULN,)-255.7(8)-253.4(w)1.5(ere)-254.3(b).4(etween)]TJ
-13.4968 -1.1795 TD
0 Tc
(2)Tj
/F4 1 Tf
.626 0 TD
()Tj
/F6 1 Tf
.6984 0 TD
-.0183 Tc
[(and)-419.1(3)]TJ
/F4 1 Tf
2.4883 0 TD
0 Tc
()Tj
/F6 1 Tf
1.1174 0 TD
-.0187 Tc
[(ULN,)-416.3(and)-419.5(3)-414(individuals)-420.3(were)]TJ
/F4 1 Tf
12.2811 0 TD
0 Tc
(>)Tj
/F6 1 Tf
.6984 0 TD
(3)Tj
/F4 1 Tf
.6311 0 TD
()Tj
/F6 1 Tf
1.1122 0 TD
-.0185 Tc
(ULN.)Tj
-19.6529 -1.1847 TD
-.018 Tc
[(The)-409(p)-5(e)4.8(r)-.6(centage)-409(of)-415(individuals)-409.3(having)-413.6(an)-408.2(elevated)-408.5(ALT)]TJ
0 -1.1795 TD
[(with)-495.8(an)-496.1(elevate)4.8(d)-501.6(AST)-495.5(d).2(ecreased)-496.4(a)0(s)-497.2(t)-.5(he)-497(level)-497.4(o).9(f)-497.8(A)1.7(LT)]TJ
0 -1.1847 TD
[(decreased.)-374.2(In)-372(the)-372.8(g).3(roup)-372.3(of)-368.5(individuals)-367.9(with)-371.6(ALT)]TJ
/F4 1 Tf
19.7719 0 TD
0 Tc
(>)Tj
/F6 1 Tf
.6984 0 TD
(3)Tj
/F4 1 Tf
.6259 0 TD
()Tj
ET
1 i
q 1 0 0 1 59.754 699.364 cm 0 0 m
.113 1.02 l
.602 3.474 2.462 5.394 4.932 5.896 c
6.009 5.953 l
6.009 4.989 l
5.159 4.876 l
3.116 4.586 1.44 2.856 1.077 .85 c
1.02 0 l
f*
Q
q 1 0 0 1 293.669 705.316 cm 0 0 m
1.02 -.057 l
3.204 -.362 5.663 -2.708 5.839 -4.932 c
5.953 -5.953 l
4.932 -5.953 l
4.876 -5.102 l
4.573 -3.084 2.869 -1.38 .85 -1.077 c
0 -.964 l
f*
Q
65.764 704.353 227.905 .96381 re
f
q 1 0 0 1 65.764 537.732 cm 0 0 m
-1.02 .113 l
-3.474 .397 -5.449 2.568 -5.896 4.932 c
-6.009 5.953 l
-4.989 5.953 l
-4.932 5.102 l
-4.532 3.106 -2.916 1.363 -.85 1.077 c
0 1.02 l
f*
Q
q 1 0 0 1 299.622 543.685 cm 0 0 m
-.113 -1.02 l
-.243 -3.15 -2.802 -5.709 -4.932 -5.839 c
-5.953 -5.953 l
-5.953 -4.932 l
-5.102 -4.876 l
-3.097 -4.541 -1.371 -2.882 -1.077 -.85 c
-1.02 0 l
f*
Q
65.764 537.732 227.905 1.0204 re
f
59.754 543.685 1.0205 155.679 re
f
298.601 543.685 1.0205 155.679 re
f
q
78.746 695.338 m
280.63 695.338 l
280.63 586.942 l
78.746 586.942 l
W n
q
202.027 0 0 108.397 78.746 586.942 cm
/Im1 Do
Q
Q
BT
/F3 1 Tf
9.9626 0 0 9.9626 76.7055 569.0266 Tm
[(FIG)-7.2(.)-330.4(1)0(.)]TJ
/F5 1 Tf
3.8696 0 TD
[(Per)-7(cent)-307.2(of)-300.4(indivi)-7.6(duals)-303.5(versu)-10.7(s)-299.2(the)-304.7(length)]TJ
-3.8696 -1.3031 TD
[(of)-306.1(their)-305.7(CBD)-302.3(use.)]TJ
ET
59.754 153.298 490.167 .22675 re
f
59.754 75.061 490.167 .22678 re
f
277.852 135.439 207.496 .22678 re
f
59.754 118.715 490.167 .28348 re
f
BT
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 159.9874 Tm
[(Table)-306.5(1.)-500.5(Number)-300.3(of)-302.7(Individuals)-304.8(and)-302(Average)-306.8(Daily)-300.1(CBD)-302.1(Dose)-304.2(by)-297(Composition)-305.2(of)-302.7(CBD)]TJ
/F1 1 Tf
7.9702 0 0 7.9702 59.7543 124.9511 Tm
[(Compositio)10.3(n)-334.3(o)0(f)-335.2(CBD)]TJ
/F8 1 Tf
14.1338 0 TD
(N)Tj
/F1 1 Tf
6.7433 0 TD
(%)Tj
14.7455 2.1197 TD
[(CBD)-330.4(dosage)-325(\(mg/day\))]TJ
/F8 1 Tf
22.5913 -2.1197 TD
(p)Tj
/F1 1 Tf
.8393 0 TD
[(vs.)-299(FS)]TJ
-31.689 0 TD
[(Mean)-5338(SD)-5862.1(Range)-5331.9(Median)]TJ
/F5 1 Tf
-27.3642 -2.1268 TD
[(All)-12630.8(839)-5007(100%)-5147.8(50.3)-5144.3(40.77)-5324.3(2.5390)-5552(36.3)-6574(NA)]TJ
0 -1.1239 TD
[(FS)-12724.8(467)-4814.9(55.7%)-5142.9(40.0)-5144.3(36.82)-5324.3(2.5210)-5552(40.1)-6574(NA)]TJ
T*
[(CBD)-300.9(isolate)-8927.9(340)-4814.9(40.5%)-5142.9(63.9)-5144.3(42.89)-5516.3(15390)-5556.9(50.0)]TJ
/F4 1 Tf
58.4629 0 TD
(<)Tj
/F5 1 Tf
.7184 0 TD
(0.001)Tj
-59.1813 -1.1239 TD
[(Broad)-300.7(spectrum)-7530.2(32)-5324.9(3.8%)-5147.8(56.5)-5144.3(26.50)-4812.1(16.5140)-5554.1(50.0)]TJ
/F4 1 Tf
58.4629 0 TD
(<)Tj
/F5 1 Tf
.7184 0 TD
(0.001)Tj
-58.0503 -2.2477 TD
[(CBD,)-296(cannab)12.3(idiol;)-303.4(FS,)-293.2(full)-296.2(spectrum;)-298.3(SD,)-294(standard)-296.2(deviation.)]TJ
/F3 1 Tf
9.9626 0 0 9.9626 59.7543 753.8455 Tm
[(IMPA)-9.2(CT)-305.7(OF)-302.8(ORAL)-308.2(CBD)-300.8(ON)-306.5(LIVER)-305.2(FUNC)-9.7(TION)-29149.3(3)]TJ
ET
endstream
endobj
37 0 obj
<>stream
Adobe d C
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? N's+m,Fu~
=rM53C{WUaq]ZK>ni
TԜ4е